Medical Articles
The Changing Face of T.A.C.E
Improved technology
- Drug eluding emboli
- DC Bead loaded with irinotecan (mCRC)
- DC Bead loaded with doxorubicin (HCC)
- Radioactive microspheres
- SIR Sphere
- Therasphere
TACE – Arterial tumour supply

Example of Chemoembolization:

Early results - HCC
- Previous studies on TACE found
- The TACE six month response rate is 35%
- The TACE six month complications rate is 27.5%
- PRECISION I results have been published in the Journal of Hepatology are as follows
- Six month response rate is 75% (66.6% on ITT)
- Six month complication rate is 7%
- Survival rate is 92.5% at 1 year and 88.9% at 2 years
- PRECISION II results are as follows
- Six month response rate is 36% (RECIST) Compares to 27%, lo et al, 2002
Efficacy Tumour Response

Efficacy Survival

TACE Versus Best Supportive Therapy

Hepatocellular Carcinoma
Treatment Paradigm

Positioning of DC Bead Irinotecan in the Treatment of Stage IV mCRC
- 10-15% patient treated by surgical resection
- For patients with unresectable disease three or more lines of systemic chemotherapy
- Late stage/Salvage Therapy: 4% (15,000)
patients - Irinotecan loaded DC Bead™
Current indications
- Salvage therapy for HCC and mCRC
- Clinical trial
Q2 2008 will see the release of data from two large prospective randomised control trials
PrecisionV
Lencioni – DC Bead + RFA